Once again, in San Diego, the ASH meeting served as a pivotal platform for unveiling crucial updates in multiple myeloma (MM). Among the noteworthy highlights were advancements in various new therapeutic approaches, including bispecific antibodies (BsAbs), CAR-T cell therapy, new insights in the treatment of smoldering MM as well as newly diagnosed MM (NDMM), and finally emerging new treatments.
(BELG J HEMATOL 2024;15(1):4–8)
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
